Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2013 17:30 ET | Source: MediciNova, Inc.

MediciNova Reports Second Quarter 2013 Results

SAN DIEGO, Aug. 8, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code...
July 18, 2013 19:00 ET | Source: MediciNova, Inc.

MediciNova Announces Initiation of a Cooperative Phase 2b Trial of MN-166 in Progressive Multiple Sclerosis

SAN DIEGO, July 18, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Tokyo Stock...
June 18, 2013 18:00 ET | Source: MediciNova, Inc.

UCLA Presents Data on MediciNova's MN-166 in Methamphetamine Addiction at the 75th Annual Meeting of the College on Problems of Drug Dependence

SAN DIEGO, June 18, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka...
May 08, 2013 17:30 ET | Source: MediciNova, Inc.

MediciNova Reports First Quarter 2013 Results

SAN DIEGO, May 8, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code...
March 28, 2013 17:30 ET | Source: MediciNova, Inc.

MediciNova Reports Fourth Quarter and Full Year 2012 Results

SAN DIEGO, March 28, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code...
March 20, 2013 19:00 ET | Source: MediciNova, Inc.

MediciNova Announces MN-166 (ibudilast) Opioid Withdrawal and Analgesia Data Presentation at the American Academy of Neurology Annual Meeting

SAN DIEGO, March 20, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka...
February 25, 2013 18:00 ET | Source: MediciNova, Inc.

FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for the Treatment of Methamphetamine Dependence

SAN DIEGO, Feb. 25, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka...
January 03, 2013 18:00 ET | Source: MediciNova, Inc.

MediciNova Provides Development Update

SAN DIEGO, Jan. 3, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka...
December 09, 2012 18:30 ET | Source: MediciNova, Inc.

MediciNova Receives Notice of Patent Allowance for Method of Treating Acute Exacerbations of Asthma

SAN DIEGO, Dec. 9, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka...
November 20, 2012 18:00 ET | Source: MediciNova, Inc.

MediciNova Announces Initiation of a Clinical Trial of MN-166 in Opioid Abusers With Columbia University and the New York State Psychiatric Institute

SAN DIEGO, Nov. 20, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code...